Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 656-kidney-and-ureter-procedures-for-neoplasm-with-mcc
    Ask Trek AI about this page

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    DRG 656 encompasses kidney and ureter surgical procedures performed for neoplasm when a Major Complication or Comorbidity is present, affecting clinical complexity and resource needs. Accurate capture of principal diagnosis, procedure codes, and Major Complication or Comorbidity status matters for inpatient reimbursement under Medicare Severity Diagnosis-Related Group-based payment.

    Customize your policy alerts

    Sign up for drg 656 policy alerts

    Get alerted when payer policies referencing 656 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 656 Overview

    DRG 656 covers inpatient admissions for kidney and ureter procedures performed for neoplasm when a Major Complication or Comorbidity is present. This Diagnosis-Related Group typically includes partial or radical nephrectomy and other urologic tumor resections complicated by significant acute or chronic conditions that increase resource use. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates relative weight and reimbursement compared with lower-severity groups. Hospitals and coders must correctly capture principal diagnosis, procedure codes, and accompanying Major Complication or Comorbidity to determine appropriate Medicare Severity Diagnosis-Related Group assignment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative and intraoperative care optimization trials focused on reducing surgical morbidity for nephrectomy patients with renal neoplasms and major complications: these studies evaluate protocols such as enhanced recovery after surgery (ERAS) pathways, blood loss minimization strategies, and perioperative monitoring in patients undergoing partial or radical nephrectomy complicated by severe comorbid conditions. The patient population includes adults with kidney or upper-tract tumors who present with physiological instability, tumor-related hemorrhage, or require complex reconstruction; outcomes measured include complication rates, length of stay, ICU utilization, and short-term mortality. This research matters to providers and payers because it targets interventions that can lower high-cost postoperative complications and readmissions typical in DRG 656, thereby improving resource use and clinical outcomes.
    • Comparative effectiveness trials of surgical approaches and extent of resection for malignant kidney and ureter tumors with major complications: these studies compare open versus minimally invasive (laparoscopic/robotic) approaches, nephron-sparing versus radical procedures, or staged versus immediate definitive surgery specifically in patients presenting with tumor-related complications such as invasion, infection, or obstruction. The enrolled population comprises patients with high-risk renal or ureteral neoplasms whose operative complexity and MCCs may influence margin status, renal function preservation, and perioperative morbidity; endpoints include oncologic control, renal functional outcomes, complication profiles, and total hospitalization costs. Results inform surgeons, hospital administrators, and payers about which operative strategies provide the best balance of clinical effectiveness and cost-efficiency for this high-acuity DRG cohort.
    • Post-discharge outcomes, rehabilitation, and transitional care studies addressing functional recovery, renal replacement needs, and readmission prevention after complex kidney/ureter cancer surgery with MCC: these observational cohorts and interventional trials test discharge planning models, early outpatient monitoring, home-based nursing or telehealth follow-up, and criteria for early initiation of dialysis when indicated. They focus on survivors of complicated nephrectomy or ureteral cancer surgery who have acute kidney injury, decreased baseline renal reserve, or other major complications that increase risk of readmission and long-term dialysis dependence; measured outcomes include 30- and 90-day readmissions, progression to chronic kidney disease or dialysis, patient-reported functional status, and post-acute care utilization. Findings are directly relevant to payers and care managers aiming to reduce costly readmissions and long-term dialysis expenditures while improving continuity of care for this vulnerable DRG population.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.